Global Healthcare Licensing Analytical Report 2019 with Focus on Immunotherapy - ResearchAndMarkets.com

DUBLIN--()--The "Analytical Report for Healthcare Licensing with Focus on Immunotherapy" report has been added to ResearchAndMarkets.com's offering.

Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies. This report presents an in-depth study of licensing deals in the area of immunotherapy. 160+ licensing news with a focus on Immunotherapy, during January 1, 2019, to August 31, 2019, are reported and analyzed to provide a snapshot view of the current business trends.

Analytical data coverage:

  • January 1, 2019, to August 31, 2019, licensing deals and negotiations
  • 160+ worldwide Immunotherapy focused healthcare licensing news of companies across North America (45%), Europe (32%), Asia (21%)
  • Small-mid-large cap companies covered - Large Cap (12%)
  • Listed and non-listed companies included
  • 4 healthcare sub-sectors covered - Pharmaceuticals (17%), Biotech (56%), Healthcare Services (21%), Medical Devices (5%)
  • 14 medicine groups studied - Oncology (51%), Allergy & Immunology (25%), Infectious Disease (9%), Hematology (6%)
  • 8+ variables analyzed

User benefits:

  • Immediate access to current global licensing trends for Immunotherapy
  • Succinct summaries of licensing deals and negotiations held worldwide
  • Quick to-the-point analytical references
  • In-depth updates on the wider perspective of Immunotherapy
  • Directions to the emerging business prospects

Key analysis in the report:

  • Leading countries in Immunotherapy focused licensing
  • Most active healthcare sub-sectors in Immunotherapy focused licensing
  • Distribution of Immunotherapy focused licensing deals among market cap groups
  • Comparisons of different medicine groups in Immunotherapy focused licensing
  • Companies currently engaging the most in Immunotherapy focused licensing
  • Dynamics of varied licensing payments arrangements worldwide

Report useful to:

  • Immunotherapy focused healthcare companies seeking licensing opportunities
  • Immunotherapy focused healthcare companies seeking a new market base
  • Executives of healthcare companies negotiating to license for Immunotherapy
  • Investors analyzing varied kinds of transaction options for Immunotherapy focused licensing

Key Topics Covered:

Introduction

Research Design

Chapter 1: Analysis of healthcare inventions with focus on Immunotherapy licensed during the past 8 months

1.1 Number of licensing deals with a focus on Immunotherapy

1.2 Countries with most licensing deals with a focus on Immunotherapy

1.3 Healthcare sub-sectors with most licensing deals with a focus on Immunotherapy

1.4 Market capitalization groups with most licensing deals with a focus on Immunotherapy

1.5 Medicine groups with most licensing deals with a focus on Immunotherapy

1.6 Leading companies with most licensing deals with a focus on Immunotherapy

1.7 Licensing payment arrangements most followed in licensing deals with a focus on Immunotherapy

Chapter 2: Key licensing deals with a focus on Immunotherapy during the past 8 months - By type of licensing deal

Chapter 3: Global healthcare inventions with focus on Immunotherapy licensed during the past 8 months - By region and company name

Chapter 4: Summary and conclusions

Appendices

Appendix 1 List of companies/institutes covered

a) By region, country and company name

b) By sub-industry, country and company name

c) By market capitalization group, country and company name

d) By medicine group, country and company name

e) By terms of payment, country and company name

Appendix 2 List of non-listed companies covered - By country and company name

Appendix 3 List of not-for-profit institutes covered - By country and institute name

For more information about this report visit https://www.researchandmarkets.com/r/c2lhy9

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900